James Murrough

James W. Murrough, MD, PhD, is a clinician–scientist specialising in mood and trauma-related disorders with a sustained programme of translational clinical research. He has led multiple randomised controlled trials and early-phase studies investigating intravenous and intranasal ketamine for treatment-resistant major depression and post-traumatic stress disorder, and has participated in early human work on other psychoactive compounds. Murrough's work bridges clinical trials, biomarker and neuroimaging studies, and systematic evidence syntheses to clarify both efficacy and underlying neurobiological mechanisms of rapid-acting antidepressant treatments.

Affiliated with academic medical centres and Veterans Affairs research programmes, Murrough has contributed important multicentre and dose/frequency studies, examined repeated-administration strategies for chronic conditions, and helped integrate findings from clinical trials into broader discussions of psychedelic-assisted psychotherapy and emerging pharmacotherapies. His research has informed clinical practice, trial design, and ongoing efforts to identify predictors and moderators of treatment response for novel neuropsychiatric interventions.